stoxline Quote Chart Rank Option Currency Glossary
Senti Biosciences, Inc. (SNTI)
0.44  0.01 (2.3%)    12-01 16:00
Open: 0.446
High: 0.446
Volume: 201,810
Pre. Close: 0.4301
Low: 0.4053
Market Cap: 20(M)
Technical analysis
2023-12-01 4:22:46 PM
Short term     
Mid term     
Targets 6-month :  0.73 1-year :  0.99
Resists First :  0.62 Second :  0.84
Pivot price 0.38
Supports First :  0.27 Second :  0.22
MAs MA(5) :  0.38 MA(20) :  0.4
MA(100) :  0.54 MA(250) :  0.98
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  31.5 D(3) :  19.1
RSI RSI(14): 56
52-week High :  2.31 Low :  0.27
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SNTI ] has closed below upper band by 22.8%. Bollinger Bands are 31.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.45 - 0.45 0.45 - 0.45
Low: 0.4 - 0.4 0.4 - 0.4
Close: 0.44 - 0.44 0.44 - 0.44
Company Description

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.

Headline News

Mon, 13 Nov 2023
Senti Bio Announces Third Quarter 2023 Results and Pipeline ... - Yahoo Finance

Wed, 08 Nov 2023
Penny Stocks To Buy Now? 4 Under $1 To Watch Today - Penny Stocks

Tue, 07 Nov 2023
US Stocks Mixed; D.R. Horton Earnings Top Views - D.R. Horton (NYSE:DHI), Alto Ingredients (NASDAQ:ALTO) - Benzinga

Tue, 07 Nov 2023
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Ses - Benzinga

Tue, 07 Nov 2023
Why Is Tharimmune (THAR) Stock Up 113% Today? - InvestorPlace

Tue, 07 Nov 2023
Why Is Alto Ingredients (ALTO) Stock Down 45% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 45 (M)
Held by Insiders 2.645e+007 (%)
Held by Institutions 27.7 (%)
Shares Short 226 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.976e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 114.1 %
Return on Equity (ttm) -28.4 %
Qtrly Rev. Growth 2.62e+006 %
Gross Profit (p.s.) -32.11
Sales Per Share -31.37
EBITDA (p.s.) -1.18175e+007
Qtrly Earnings Growth -2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -54 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.59
Stock Dividends
Dividend 0
Forward Dividend 416530
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android